RE:RE:RE:RE:RE:RE:RE:Merger info: no packages sent out, nothing on SEDARPBaelishh wrote: Right?!!!!
So given that, what is the likelihood of any new product before all of the money is burnt?
- New powder formulations of both of CZO's active ingredients are about to be launched with German giant Symrise allowing access to new markets.
- The malted avenanthramide technology reached commercial scale last year allowing the production of four plants to now be produced in a single plant. This will allow access to the neutraceutical market for the first time.
- CZO has talked about potentally supplying customers directly in the future.
- AEZS's pediatric diagnostic test trial was expected to be fully enrolled by the end of 2023. With successful results and regulatory approval the test will be allowed to be sold into the pediatric market for the first time. This is the most important market for a growth hormone deficiency test and will be a platform to promote the test to the adult market where the test is already approved. For adults a lack of growth horomone can also be important to health and lifespan with affects on body composition, muscle tone and cardiovascular parameters.
- PGX is expected to reach 100L capacity in Q3 with Natex which will allow the sale of immune booster for the first time at limited scale.
- The new company also has the potential of signing multiple partnerships with upfront, and milestone payments in addition to royalties. With clinical trial results AEZS's diagnostic test will be ready for re-licensing in North America. The avenanthramide pill is expected to have human safety/tolerability and preliminary efficacy data this year providing a basis for a deal. The wound healing program is completing studies epexcted to provide the basis for a partnership. PGX deals as for CoQ10 can come with upfront, milestone, and royalty payments. AEZS has also talked about potentially licensing certain of its pipeline programs as the AIM Biologicals program.
- The wound healing data is also expected to reinforce and create new opportunities for existing products.
Gilles Gagnon, Chief Executive Officer of Ceapro: “The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs..." news release "The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business..." news release